Payment overview · 2025
General Payments
$634.15
12 reported records · 8 companies
Healthcare provider profile · identity verified
Rajinder Shiwach, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · DESOTO, TX · NPI 1992740278
Verified facts
What the public records show
CMS Open Payments records show Rajinder Shiwach, MD received $634.15 in general payments during 2025 across 12 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $241.31 | 38.0% | 2 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $115.43 | 18.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $105.49 | 16.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.20 | 9.2% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $45.17 | 7.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $28.77 | 4.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.95 | 3.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.83 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.79 | 11 |
| Travel and Lodging | $217.36 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Scientific Affairs, LLC | $115.43 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.20 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $45.17 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 326 | 70 |
| Clonazepam | Clonazepam | 240 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 177 | 57 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 115 | 18 |
| Diazepam | Diazepam | 78 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 76 | 11 |
| Buprenorphine Hcl | Buprenorphine Hcl | 67 | suppressed |
| Lorazepam | Lorazepam | 56 | 22 |
| Buspirone Hcl | Buspirone Hcl | 44 | 23 |
| Trazodone Hcl | Trazodone Hcl | 43 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 24 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | 16 |
| Belsomra | Suvorexant | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | 12 |
| Temazepam | Temazepam | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Gabapentin | Gabapentin | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $634.15 · 12 records | E.R. Squibb & Sons, L.L.C. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AUSTEDO XR, CAPLYTA, COBENFY, INGREZZA, INVEGA SUSTENNA, VRAYLAR | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error